Company Overview of Pherin Pharmaceuticals, Inc.
Pherin Pharmaceuticals, Inc. engages in the research, development, and manufacture of pherine-based pharmaceutical products for the treatment of behavioral, neuropsychiatric, and neuroendocrine disorders. It offers a family of pharmaceuticals for the treatment of premenstrual syndrome and premenstrual dystrophic disorders, social phobia, hot flashes, depression, and benign prostatic hypertrophy, as well as for body weight management and cognitive enhancement. The company was founded in 1991 and is based in Los Altos, California.
4962 El Camino Real
Los Altos, CA 94022
Founded in 1991
Key Executives for Pherin Pharmaceuticals, Inc.
Director and President of Pherin Farmaceutica SA
Executive Vice President of Research and Secretary
Compensation as of Fiscal Year 2014.
Pherin Pharmaceuticals, Inc. Key Developments
Pherin Pharmaceuticals, Inc. Reports Favorable Clinical, Regulatory, and Intellectual Property Actions on Novel Intranasal Medication for Acute Treatment of Social Anxiety Disorder
Dec 6 12
Pherin Pharmaceuticals, Inc. announced that a Phase II clinical trial showed that its proprietary compound PH94B demonstrated significant benefits in the acute treatment of symptoms of Social Anxiety Disorder (Social Phobia). Based on the positive study results, the company has met with the US Food & Drug Administration to plan a Phase III pivotal study of PH94B for the acute treatment of Social Anxiety Disorder. Also, the company has received Notification of Issuance from the US Patent & Trademark Office for its patent application covering the acute treatment of Social Anxiety Disorder with PH94B and similar allowances in the European Union, Japan, China and other major countries. Phase II Study Results The Phase II study was conducted in three centers to evaluate the effect of PH94B for the acute treatment of symptoms of Social Anxiety Disorder, as well as its safety and tolerability. It was a randomized, double blind, single-administration, placebo-controlled study in 91 Social Anxiety Disorder patients, using validated psychometric scales. PH94B (800 nanograms) was evaluated against placebo. PH94B significantly improved the primary efficacy endpoints (social performance and social interaction anxiety) within 10 minutes of administration. Secondary efficacy endpoints for the trial included additional anxiety response assessments and other symptom assessments at various time points. Safety evaluations were made throughout the clinical trial period. PH94B showed clinical efficacy to reduce Social Anxiety Disorder symptoms in 75.6% patients as compared with placebo (37% only). The PH94B treated group improvement exceeded the placebo treated group during a Public Speaking challenge (t = 3.16; p < 0.01) and also during a Social Interaction challenge (t = 2.67; p < 0.01). There were no adverse events associated with PH94B and the medication was well tolerated. The company attributes these results to the formulation of PH94B.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries